Table S4 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors

Jong Chul Park; David Berz; Manish R. Sharma; Jyoti Dhar Malhotra; Anthony W. Tolcher; Ralph J. Hauke; Justin Call; John Turner Hamm; Rachel E. Sanborn; Naomi Balzer Haas; Frank Yung-Chin Tsai; Douglas R. Adkins; D. Ross Camidge; Alexander I. Spira; Lane Senne; James L. Kalabus; Brianne O’Neill; Heather Kinkead; Josep Garcia; Erminia Massarelli

doi:10.1158/2767-9764.31387924

Table S4 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors

2026 Open access

Read full text

Authors: Jong Chul Park, David Berz, Manish R. Sharma, Jyoti Dhar Malhotra, Anthony W. Tolcher, Ralph J. Hauke, Justin Call, John Turner Hamm, Rachel E. Sanborn, Naomi Balzer Haas, Frank Yung-Chin Tsai, Douglas R. Adkins

+8 more

D. Ross Camidge, Alexander I. Spira, Lane Senne, James L. Kalabus, Brianne O’Neill, Heather Kinkead, Josep Garcia, Erminia Massarelli

DOI: 10.1158/2767-9764.31387924

Cited by: 0

Abstract

Table S4 summarizes the INBRX-105–related hepatic treatment-emergent adverse events

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Immunotherapy and Immune Responses Monoclonal and Polyclonal Antibodies Research

Publication details

Publication date: 23 February 2026
Language: EN